SCHEMBL14948533

SCHEMBL14948533

CCOC(=O)CCC(=O)ON1C(=O)CCC1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.43
LMNA P02545 3/20 0.42
POLB P06746 1/20 0.42
ALDH1A1 P00352 2/20 0.41
NOTUM Q6P988 1/20 0.41
CYP1A2 P05177 2/20 0.40
GSK3A P49840 1/20 0.40
GSK3B P49841 1/20 0.40
GAA P10253 2/20 0.39
MGAM O43451 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
KAT2B Q92831 1/20 0.38
ELANE P08246 1/20 0.38
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6358200 0.93 CYP1A2 (0.46) TSHRLMNAPOLBALDH1A1NOTUM
SCHEMBL17256327 0.92 CYP1A2 (0.44) TSHRALDH1A1CYP1A2GAACYP4F2
SCHEMBL14644916 0.89 PSMB8 (0.33) TSHRLMNA
SCHEMBL43576 0.87 PSMB8 (0.35) TSHRLMNAKMT2ASMN1; SMN2
SCHEMBL12060996 0.86 ALDH1A1 (0.41) LMNAALDH1A1KMT2ASMN1; SMN2L3MBTL1
SCHEMBL141048 0.85 ADRA2A (0.36) ALDH1A1SMN1; SMN2
SCHEMBL9329901 0.85 DGKA (0.37) TSHRALDH1A1CYP1A2GAACYP2C19
SCHEMBL31522720 0.85 PSMB8 (0.34) LMNAKMT2ASMN1; SMN2
SCHEMBL18915652 0.83 ALDH1A1 (0.44) LMNAALDH1A1GAAKMT2ASMN1; SMN2
SCHEMBL70665 0.83 ALDH1A1 (0.43) ALDH1A1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170319696-A1 Derivatized Hyperbranched Polyglycerols THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2017-11-09 US disclosed
US-9561278-B2 Derivatized hyperbranched polyglycerols THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2017-02-07 US disclosed
US-20160114040-A1 Derivatized Hyperbranched Polyglycerols CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) 2016-04-28 US disclosed
US-9186410-B2 Derivatized hyperbranched polyglycerols THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2015-11-17 US disclosed
US-20140155457-A1 Method of Relieving, Improving, Preventing or Treating Xerostomia SUNBIO INC. (KR) 2014-06-05 US disclosed
US-20130122112-A1 Derivatized Hyperbranched Polyglycerols CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) 2013-05-16 US disclosed
US-8202963-B2 Tissue adhesives with modified elasticity ACTAMAX SURGICAL MATERIALS, LLC (US) 2012-06-19 US disclosed
US-20110269916-A1 TISSUE ADHESIVES WITH MODIFIED ELASTICITY ACTAMAX SURGICAL MATERIALS, LLC 2011-11-03 US disclosed
CN-1142775-A Preparation and use of immunoconjugates IMMUNOMEDICS INC (US) 1997-02-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155457-A1 Method of Relieving, Improving, Preventing or Treating Xerostomia GLA, LPO, MUC1 TSHR 1811/4885LMNA 3918/4885POLB 434/4885
US-20160114040-A1 Derivatized Hyperbranched Polyglycerols DDOST, UGCG, DAD1 TSHR 4684/4885LMNA 1086/4885POLB 1960/4885
US-20130122112-A1 Derivatized Hyperbranched Polyglycerols DDOST, UGCG, DAD1 TSHR 4684/4885LMNA 1086/4885POLB 1960/4885
US-20170319696-A1 Derivatized Hyperbranched Polyglycerols DDOST, UGCG, DAD1 TSHR 4684/4885LMNA 1086/4885POLB 1960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.